共 50 条
- [31] Guselkumab efficacy and safety through 5 years among psoriasis patients with and without metabolic syndrome at baseline: Results from VOYAGE 1 and VOYAGE 2JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB170 - AB170Merola, Joseph F.Thaci, DiamantChoi, OliviaChan, DaphneYang, Ya-WenMiller, MeganYou, YinLi, ShuBlauvelt, AndrewPuig, Luis
- [32] DYNAMICS OF NAIL PSORIASIS WITH GUSELKUMAB TREATMENT AND WITHDRAWAL IN ASSOCIATION WITH SKIN RESPONSE AND PATIENT-REPORTED OUTCOMES: A POST HOC ANALYSIS OF THE VOYAGE 2 PHASE 3 TRIALANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 830 - 830Tillett, W.Egeberg, A.Sonkoly, E.Gorecki, P.Tjarnlund, A.Buyze, J.Wegner, S.Mcgonagle, D.
- [33] Low-risk of serious infections and infections of interest in psoriasis patients treated with Guselkumab for 5 years in VOYAGE 1 and 2 phase 3 trialsEXPERIMENTAL DERMATOLOGY, 2021, 30 : 35 - 35Langley, R.Thaci, D.Blauvelt, A.Tsai, T. -F.Miller, M.Yu, J.Shen, Y. -K.You, Y.Yang, Y. -W.Papp, K. A.Puig, L.Foley, P.
- [34] Maintenance of complete skin clearance throughout 3 years of continuous guselkumab treatment in patients with moderate-to-severe psoriasis: A post hoc analysis of 5-year data from the VOYAGE 1 trialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB108 - AB108Costanzo, AntonioConrad, CurdinGramiccia, TaliaJazra, Mariade Jong, Elke M. G. J.Iversen, LarsOzturk, BulentWapenaar, RobertWegner, SvenTorres, TiagoPuig, Luis
- [35] TWO-YEAR EFFICACY AND SAFETY OF GUSELKUMAB FOR TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: PHASE 3 VOYAGE 1 TRIALANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1580 - 1581Griffiths, C. E.Papp, K. A.Kimball, A. B.Randazzo, B.Wasfi, Y.Li, S.Shen, Y. -K.Blauvelt, A.
- [36] Malignancy rates and comparisons to the general US population through 3 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis from the VOYAGE 1 and 2 trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB145 - AB145Papp, Kim A.Reich, KristianGordon, Ken B.Kimball, Alexa B.Ramachandran, ParaneedharanBlauvelt, AndrewLebwohl, MarkSong, MichaelRandazzo, BruceShen, Yaung-Kaung
- [37] Frequency of gastrointestinal-related serious adverse events among guselkumab-treated patients with moderate to severe psoriasis: A pooled analysis of Voyage 1 and Voyage 2 through 3 yearsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB35 - AB35Foley, PeterReich, KristianBlauvelt, AndrewBagel, JerryLangley, RichardSong, MichaelRamachandran, ParaneedharanShen, Yaung-KaungYou, YinLebwohl, MarkGriffiths, Christopher E. M.
- [38] SPEED OF RESPONSE OF GUSELKUMAB COMPARED WITH ADALIMUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: RESULTS THROUGH WEEK 24 FROM THE PHASE 3, DOUBLE-BLINDED, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED VOYAGE 1 AND VOYAGE 2 TRIALSACTA DERMATO-VENEREOLOGICA, 2018, 98 : 21 - 21Blauvelt, AndrewTyring, StephenPhilipp, SandraAdam, DavidSong, MichaelWasfi, YasmineYou, YinShen, Yaung-KaungBagel, Jerry
- [39] Malignancy rates through 4 years of follow-up in guselkumab-treated moderate to severe psoriasis patients from the VOYAGE 1 and 2 trials and comparisons to the general United States populationJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB157 - AB157Papp, Kim A.Reich, KristianGordon, Kenneth B.Lebwohl, MarkSong, MichaelMiller, MeganRamachandran, ParaneedharanShen, Yaung-KaungLin, Connie B.Blauvelt, Andrew
- [40] Speed of response of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: Results through week 24 from the phase 3, double-blinded, placebo- and active comparator-controlled VOYAGE 1 and VOYAGE 2 trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB267 - AB267Blauvelt, AndreaTyring, StephenPhilipp, SandraAdam, DavidSong, MichaelWasfi, YasmineYou, YinShen, Yaung-KaungBagel, Jerry